Bibliography

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed in reverse chronological order. Articles from the bibliography that are reprinted in this issue are in bold type.

Charney DS: Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry 2004; 161:195–216

Gould RA, Safren SA, Washington DO, Otto MW: A meta-analytic review of cognitive-behavioral treatments, in Generalized Anxiety Disorder: Advances in Research and Practice. Edited by Heimberg RG, Turk CL, Mennin DS. New York, Guilford, 2004, pp 248–264

Jenike MA: Clinical practice: obsessive-compulsive disorder. N Engl J Med 2004; 350:259–265

Borkovec TD, Newman MG, Castonguay LG: Cognitive-behavioral therapy for generalized anxiety disorder with integrations from interpersonal and experiential therapies. CNS Spectr 2003; 8:382–389

Freeman JB, Garcia AM, Fucci C, Karitani M, Miller L, Leonard HL: Family-based treatment of early-onset obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003; 13(suppl 1):S71–S80

Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV: Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003; 160:1919–1928

Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB: Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectr 2003; 8:363–371,381

Hollander E, Rossi NB, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003; 6:397–401

Kaplan A, Hollander E: A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003; 54:1111–1118

Kent JM, Rauch SL: Neurocircuitry of anxiety disorders. Curr Psychiatry Rep 2003; 5:266–273

Pigott TA: Anxiety disorders in women. Psychiatr Clin North Am 2003; 26:621–672, vi–vii

Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon W, Sullivan G, Means-Christensen A, Bystritsky A: Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003; 54:327–332

Schneier FR: Social anxiety disorder. BMJ 2003; 327(7414): 515–516

Tenney NH, Denys DA, van Megen HJ, Glas G, Westenberg HG: Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder. Int Clin Psychopharmacol 2003; 18:29–33

Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ; World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders. World J Biol Psychiatry 2002; 3:171–199

Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, Jenike MA, Rauch SL: Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry 2002; 159:269–275

Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J: Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 2002; 63(suppl 6):20–29

Reul JM, Holsboer F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002; 2:23–33

Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG: Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 2002; 59:1027–1034

Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J: Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63(suppl 8):24–34

Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU: Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62(suppl 11):53–58

Katzelnick DJ, Kobak KA, DeLeire T, Henk HJ, Greist JA, Davidson JRT, Schneier FR, Stein MB, Helstad CP: Impact of generalized social anxiety disorder in managed care. Am J Psychiatry 2001; 158:1999–2007

Kendler KS: Twin studies of psychiatric illness: an update. Arch Gen Psychiatry 2001; 58:1005–1014

Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40:222–229

Roth DA, Heimberg RG: Cognitive-behavioral models of social anxiety disorder. Psychiatr Clin North Am 2001; 24:753–771

Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter LR Jr: Cerebral metabolism in major depression and obsessive-compulsive disorder occurring. Biol Psychiatry 2001; 50:159–170

Tolin DF, Abramowitz JS, Kozak MJ, Foa EB: Fixity of belief, perceptual aberration, and magical ideation in obsessive-compulsive disorder. J Anxiety Disord 2001; 15:501–510

Van Noppen BL, Steketee G: Individual, group, and multifamily cognitive-behavioral treatments, in Current Treatments of Obsessive-Compulsive Disorder, 2nd ed. Edited by Pato MT, Zohar J. Washington, DC, American Psychiatric Publishing, 2001, pp 133–172

Walkup JT, Labellarte MJ, Riddle MA, Pine DS, Greenhill L, Klein R, Davies M, Sweeney M, Abikoff H, Hack S, Klee B, McCracken J, Bergman L, Piacentini J, March J, Compton S, Robinson J, O’Hara T, Baker S, Vitiello B, Ritz L, Roper M, for the Research Unit on Pediatric Psychopharmacology Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344:1279–1285

Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283:2529–2536

Gorman JM, Kent JM, Sullivan GM, Coplan JD: Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157:493–505

Maier W, Gansicke M, Freyberger HJ, Linz M, Heun R, Lecrubier Y: Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity? Acta Psychiatr Scand 2000; 101:29–36

McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor–refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57:794–801

Mendlowicz MV, Stein MB: Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000; 157:669–682

Rickels K, Pollack MH, Sheehan DV, Haskins JT: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157:968–974

Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JRT, Ballenger JC, Fyer AJ: The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999; 60:427–435

Kessler RC, DuPont RL, Berglund P, Wittchen HU: Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156:1915–1923

Silverstone PH, Ravindran A: Once-daily venlafaxine extended release (xr) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiat 1999; 60:22–28

Stein MB, Fyer AJ, Davidson JRT, Pollack MH, Wiita B: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156:756–760

American Psychiatric Association: Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry 1998; 155(suppl 5)

Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ: Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl) 1998; 136:205–216

Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708–713

Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264–271

Murphy TK, Goodman WK, Fudge MW, Williams RC Jr, Ayoub EM, Dalal M, Lewis MH, Zabriskie JB: B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette’s syndrome? Am J Psychiatry 1997; 154:402–407

Breiter HC, Rauch SL, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN, Kendrick AD, Davis TL, Jiang A, Cohen MS, Stern CE, Belliveau JW, Baer L, O’Sullivan RL, Savage CR, Jenike MA, Rosen BR: Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53:595–606

Kendler KS: Major depression and generalized anxiety disorder: same genes, (partly) different environments—revisited. Br J Psych Suppl 1996; 30:68–75

Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169468–474

Greist J, Chouinard G, Duboff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C: Double-blind parallel comparison of 3 dosages of sertraline and placebo in outpatients with obsessive-compulsive-disorder. Arch Gen Psychiatry 1995; 52:289–295

Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF: A family study of obsessive-compulsive disorder. Am J Psychiatry 1995; 152:76–84

Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8–19

McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ: Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994; 164:459–468

Schuckit MA, Hesselbrock V: Alcohol dependence and anxiety disorders: what is the relationship? Am J Psychiatry 1994; 151:1723–1734

Leonard HL, Swedo SE, Lenane MC, Rettew DC, Hamburger SD, Bartko JJ, Rapoport JL: A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993; 50:429–439

Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson JC: PET in generalized anxiety disorder. Biol Psychiatry 1991; 29:1181–1199